BioRegenx, Inc.
BRGX
$0.0115
-$0.0005-4.17%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 11.86% | -22.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.86% | -22.73% | |||
| Cost of Revenue | -20.83% | 20.45% | |||
| Gross Profit | 25.81% | -32.99% | |||
| SG&A Expenses | -67.90% | 655.29% | |||
| Depreciation & Amortization | -- | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -72.40% | 177.78% | |||
| Operating Income | 90.85% | -542.90% | |||
| Income Before Tax | 98.55% | -4,559.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 98.55% | -4,559.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 98.55% | -4,559.56% | |||
| EBIT | 90.85% | -542.90% | |||
| EBITDA | 88.22% | -718.81% | |||
| EPS Basic | 98.41% | -4,625.00% | |||
| Normalized Basic EPS | 85.71% | -366.67% | |||
| EPS Diluted | 98.41% | -4,625.00% | |||
| Normalized Diluted EPS | 85.71% | -366.67% | |||
| Average Basic Shares Outstanding | -1.51% | 1.59% | |||
| Average Diluted Shares Outstanding | -1.51% | 1.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||